Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD133 CAR-T cells (Zhujiang Hospital)
- Development stage
- Unknown
- Lead developer
- Southern Medical University Zhujiang Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-CD133 CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy developed by Zhujiang Hospital for the treatment of relapsed or refractory acute myeloid leukemia (AML). The therapy involves genetically engineering a patient's T-cells to express a CAR that specifically recognizes CD133 (Prominin-1), a glycoprotein often expressed on the surface of leukemic stem cells and hematopoietic progenitor cells. By targeting CD133, these CAR-T cells are designed to selectively identify and eliminate AML cells, including the stem cell population that is frequently resistant to conventional chemotherapy and responsible for disease relapse. This therapy is currently being evaluated in early-phase clinical trials to assess its safety and efficacy in patients with advanced myeloid malignancies.
- Other names
- anti-CD133 chimeric antigen receptor T-cellsanti-CD-133 chimeric antigen receptor T-cellsanti-CD 133 chimeric antigen receptor T-cellsCD133-targeted CAR-T cellsCD-133-targeted CAR-T cellsCD 133-targeted CAR-T cells
02
Targets
CD133 (CD133 antigen)
Beyond the preview
Go deeper on anti-CD133 CAR-T cells (Zhujiang Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD133 CAR-T cells (Zhujiang Hospital).